Revised working paper following AVAREF meeting February 2019.
WHO has published a roadmap aiming to coordinate partners’ actions and contributions to the licensing and roll-out of Merck’s Ebola vaccine (VSV-ZEBOV) in African countries. The vaccine was developed during the West Africa Ebola epidemic of 2014-2016, during which more than 11 000 people lost their lives to the disease. The vaccine was tested in European and African countries at the time and is currently used under an “expanded access” protocol in the Democratic Republic of Congo.
WHO will expedite prequalification and licensing of the vaccine for use in countries at risk of Ebola outbreaks and will coordinate work between those countries’ regulatory authorities and the European Medicines Agency and the US Food and Drug Administration.
This document presents a consolidated summary of urgent activities
required to advance preparedness, as elaborated in each country's
national plan, with a particular focus on Priority 1 countries. It
presents the estimated requirements, needs, and gaps for each of the
Priority 1 countries and a summary for Priority 2 countries, as
aligned for the period of July to December 2019.
This document aims to provide guidance to EU/EEA public health authorities, public health professionals and healthcare practitioners for the management of persons having had contact with cases of Ebola virus disease (EVD) after visiting or working in an area that is affected by EVD; also covered is occupational exposure to the disease
This brief summarises key considerations about the social, political and economic context of Goma in relation to the outbreak of Ebola in the DRC as of March 2019. Goma is the administrative capital of North Kivu province and a major urban centre in the Great Lakes Region. The city is home to an estimated 1.5 million people and serves as an important economic and transportation hub that links eastern Congo to the broader East African sub-region. The arrival of Ebola in Goma would substantially increase the at-risk population and heighten the potential for cross-border transmission to neighbouring countries, particularly Rwanda. This brief therefore focuses on local social and political structures that can be leveraged to promote preparedness and readiness actions.
•Definir la Higiene de manos y las infecciones adquiridas en los hospitales (HAIs).
•Describir el impacto negativo de las HAIs en pacientes dados de alta.
•Discutir cómo la higiene de manos puede prevenir los HAIs.
•Identificar las barreras para el cumplimiento de la higiene de las manos.
•Describir los ”5 momentos de la Higiene de Manos”
•Identificar las formas de promover la higiene de manos en el hospital.
•Demostrar las técnicas apropiadas de la higiene de manos.
•Revise la lista de control de higiene de las manos